The analytical sensitivity to detect EGFR mutations in the cell-free plasma of NSCLC patients with methods such as Cobas® [38], ddPCR [9], and ARMS [39] revealed a pooled sensitivity of 67% and a specificity of 94% [40]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.